Raymond James & Associates’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q1 | – | Sell |
-873
| Closed | -$5.35K | – | 3915 |
|
2023
Q4 | $5.35K | Sell |
873
-417
| -32% | -$2.55K | ﹤0.01% | 3759 |
|
2023
Q3 | $6.02K | Buy |
1,290
+17
| +1% | +$79 | ﹤0.01% | 3735 |
|
2023
Q2 | $6.82K | Sell |
1,273
-66
| -5% | -$354 | ﹤0.01% | 3760 |
|
2023
Q1 | $13.2K | Buy |
1,339
+64
| +5% | +$630 | ﹤0.01% | 3769 |
|
2022
Q4 | $23.9K | Sell |
1,275
-321
| -20% | -$6.01K | ﹤0.01% | 3705 |
|
2022
Q3 | $33K | Sell |
1,596
-785
| -33% | -$16.2K | ﹤0.01% | 3693 |
|
2022
Q2 | $49K | Buy |
2,381
+8
| +0.3% | +$165 | ﹤0.01% | 3732 |
|
2022
Q1 | $102K | Sell |
2,373
-222
| -9% | -$9.54K | ﹤0.01% | 3767 |
|
2021
Q4 | $155K | Sell |
2,595
-65
| -2% | -$3.88K | ﹤0.01% | 3733 |
|
2021
Q3 | $229K | Buy |
2,660
+775
| +41% | +$66.7K | ﹤0.01% | 3564 |
|
2021
Q2 | $210K | Sell |
1,885
-92
| -5% | -$10.2K | ﹤0.01% | 3628 |
|
2021
Q1 | $220K | Sell |
1,977
-553
| -22% | -$61.5K | ﹤0.01% | 3518 |
|
2020
Q4 | $269K | Buy |
2,530
+19
| +0.8% | +$2.02K | ﹤0.01% | 3157 |
|
2020
Q3 | $350K | Buy |
2,511
+459
| +22% | +$64K | ﹤0.01% | 2841 |
|
2020
Q2 | $664K | Buy |
2,052
+205
| +11% | +$66.3K | ﹤0.01% | 2410 |
|
2020
Q1 | $165K | Hold |
1,847
| – | – | ﹤0.01% | 3081 |
|
2019
Q4 | $73K | Buy |
1,847
+340
| +23% | +$13.4K | ﹤0.01% | 3461 |
|
2019
Q3 | $37K | Buy |
1,507
+209
| +16% | +$5.13K | ﹤0.01% | 3442 |
|
2019
Q2 | $46K | Hold |
1,298
| – | – | ﹤0.01% | 3449 |
|
2019
Q1 | $58K | Sell |
1,298
-818
| -39% | -$36.6K | ﹤0.01% | 3418 |
|
2018
Q4 | $102K | Buy |
2,116
+1,165
| +123% | +$56.2K | ﹤0.01% | 3277 |
|
2018
Q3 | $63K | Buy |
+951
| New | +$63K | ﹤0.01% | 3428 |
|
2017
Q2 | – | Sell |
-843
| Closed | -$67K | – | 3214 |
|
2017
Q1 | $67K | Sell |
843
-33
| -4% | -$2.62K | ﹤0.01% | 3059 |
|
2016
Q4 | $73K | Sell |
876
-183
| -17% | -$15.3K | ﹤0.01% | 3004 |
|
2016
Q3 | $118K | Buy |
1,059
+116
| +12% | +$12.9K | ﹤0.01% | 2930 |
|
2016
Q2 | $105K | Buy |
943
+85
| +10% | +$9.46K | ﹤0.01% | 2772 |
|
2016
Q1 | $90K | Buy |
+858
| New | +$90K | ﹤0.01% | 2707 |
|